Matches in SemOpenAlex for { <https://semopenalex.org/work/W1568675316> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W1568675316 abstract "Melanoma is a genetically complex cancer harboring a multitude of somatic mutations for potential targeting by the immune system. However, melanoma cells can co-opt normal immune tolerance mechanisms to evade elimination. The immunoglobulin-like molecule PD-L1 (B7-H1), expressed by many melanomas in situ, creates a protective shield against immune attack. PD-L1 is a ligand for the programmed death-1 (PD-1) receptor expressed on activated T and B cells, and it delivers an inhibitory signal to suppress antitumor immunity. Blocking the PD-1:PD-L1 interaction can rejuvenate anti-melanoma immunity and mediate tumor regression. Multicenter clinical trials of blocking antibodies against PD-1 (nivolumab, pembrolizumab) or PD-L1 (BMS-936559, MPDL3280A, MEDI4736) have been undertaken. In an early phase trial of biweekly nivolumab administration, durable objective tumor regressions and disease stabilization were observed among 31% and 7%, respectively, of 107 patients with advanced treatment-refractory melanoma. Median overall survival in this trial was 17 months. Partial tumor regressions that are durable and persist after drug discontinuation suggest that PD-1 blockade can reset the balance between the immune system and melanoma. In some patients, “mixed” tumor regressions or initial disease progression followed by regression suggest that tumor lesions separated anatomically or chronologically may be immunologically heterogeneous. Durable objective tumor regressions reported in clinical trials of various antibodies blocking the PD-1 and PD-L1 immune checkpoints validate the importance of targeting this pathway in melanoma therapy. Ongoing investigations into pharmacodynamics and potential biomarkers of response are designed to reveal the basis for immunological heterogeneity among different patients, and among diverse tumor sites in individual patients, to enable the optimal clinical development of these drugs. Supported by research grants from Bristol-Myers Squibb, the National Institutes of Health, Stand Up 2 Cancer, the Barney Family Foundation, the Laverna Hahn Charitable Trust, Moving for Melanoma of Delaware, and the Melanoma Research Alliance. Citation Format: Suzanne L. Topalian. Response and resistance PD-1 pathway blockade. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Melanoma: From Biology to Therapy; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(14 Suppl):Abstract nr IA19." @default.
- W1568675316 created "2016-06-24" @default.
- W1568675316 creator A5052980036 @default.
- W1568675316 date "2015-07-15" @default.
- W1568675316 modified "2023-09-25" @default.
- W1568675316 title "Abstract IA19: Response and resistance PD-1 pathway blockade" @default.
- W1568675316 doi "https://doi.org/10.1158/1538-7445.mel2014-ia19" @default.
- W1568675316 hasPublicationYear "2015" @default.
- W1568675316 type Work @default.
- W1568675316 sameAs 1568675316 @default.
- W1568675316 citedByCount "0" @default.
- W1568675316 crossrefType "proceedings-article" @default.
- W1568675316 hasAuthorship W1568675316A5052980036 @default.
- W1568675316 hasConcept C121608353 @default.
- W1568675316 hasConcept C126322002 @default.
- W1568675316 hasConcept C143998085 @default.
- W1568675316 hasConcept C159654299 @default.
- W1568675316 hasConcept C170493617 @default.
- W1568675316 hasConcept C203014093 @default.
- W1568675316 hasConcept C2777658100 @default.
- W1568675316 hasConcept C2777701055 @default.
- W1568675316 hasConcept C2778468042 @default.
- W1568675316 hasConcept C2780030458 @default.
- W1568675316 hasConcept C2780057760 @default.
- W1568675316 hasConcept C2780851360 @default.
- W1568675316 hasConcept C45121317 @default.
- W1568675316 hasConcept C502942594 @default.
- W1568675316 hasConcept C71924100 @default.
- W1568675316 hasConcept C8891405 @default.
- W1568675316 hasConceptScore W1568675316C121608353 @default.
- W1568675316 hasConceptScore W1568675316C126322002 @default.
- W1568675316 hasConceptScore W1568675316C143998085 @default.
- W1568675316 hasConceptScore W1568675316C159654299 @default.
- W1568675316 hasConceptScore W1568675316C170493617 @default.
- W1568675316 hasConceptScore W1568675316C203014093 @default.
- W1568675316 hasConceptScore W1568675316C2777658100 @default.
- W1568675316 hasConceptScore W1568675316C2777701055 @default.
- W1568675316 hasConceptScore W1568675316C2778468042 @default.
- W1568675316 hasConceptScore W1568675316C2780030458 @default.
- W1568675316 hasConceptScore W1568675316C2780057760 @default.
- W1568675316 hasConceptScore W1568675316C2780851360 @default.
- W1568675316 hasConceptScore W1568675316C45121317 @default.
- W1568675316 hasConceptScore W1568675316C502942594 @default.
- W1568675316 hasConceptScore W1568675316C71924100 @default.
- W1568675316 hasConceptScore W1568675316C8891405 @default.
- W1568675316 hasLocation W15686753161 @default.
- W1568675316 hasOpenAccess W1568675316 @default.
- W1568675316 hasPrimaryLocation W15686753161 @default.
- W1568675316 hasRelatedWork W135658021 @default.
- W1568675316 hasRelatedWork W1988495902 @default.
- W1568675316 hasRelatedWork W2003154236 @default.
- W1568675316 hasRelatedWork W2075027825 @default.
- W1568675316 hasRelatedWork W2121314233 @default.
- W1568675316 hasRelatedWork W2130541026 @default.
- W1568675316 hasRelatedWork W2135573233 @default.
- W1568675316 hasRelatedWork W2327225958 @default.
- W1568675316 hasRelatedWork W2339287973 @default.
- W1568675316 hasRelatedWork W2400328547 @default.
- W1568675316 hasRelatedWork W2560367415 @default.
- W1568675316 hasRelatedWork W2607172282 @default.
- W1568675316 hasRelatedWork W2621587943 @default.
- W1568675316 hasRelatedWork W2786417046 @default.
- W1568675316 hasRelatedWork W2911237448 @default.
- W1568675316 hasRelatedWork W2999691828 @default.
- W1568675316 hasRelatedWork W3014865085 @default.
- W1568675316 hasRelatedWork W3091475495 @default.
- W1568675316 hasRelatedWork W3130761243 @default.
- W1568675316 hasRelatedWork W80073472 @default.
- W1568675316 isParatext "false" @default.
- W1568675316 isRetracted "false" @default.
- W1568675316 magId "1568675316" @default.
- W1568675316 workType "article" @default.